Vaccine focused biotech SK bioscience (KRX: 302440) has signed a second collaboration this month.
The South Korean company has entered into a collaboration with Vaxxas, an Australian biotechnology company developing a unique vaccine patch platform technology, to develop a second-generation typhoid conjugate vaccine.
The global charitable foundation Wellcome will fund the collaboration for the first two years, awarding $3.67 million to conduct the first-phase clinical trial, according to SK bioscience.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze